文献速递心脏核医学

秋水仙碱与心肌梗死后心肌灌注储备的关联:COLD-MI 试验辅助分析

Association of colchicine use with myocardial perfusion reserve after myocardial infarction: An ancillary analysis of the COLD-MI trial.
PubMed 文献 · J Nucl Cardiol · 2026-01-22

该研究为 COLD-MI 试验辅助分析,45 例急性心肌梗死患者随机接受秋水仙碱 30 天或无秋水仙碱,6 个月时行定量动态 [99mTc]Tc-tetrofosmin SPECT 和 [123I]-mIBG 显像。结果显示秋水仙碱组远程心肌 MPR 显著更高(2.37±0.61 vs 1.92±0.53,P=0.01),远程区域去神经表面积更低(43%[29-50] vs 50%[38-64],P=0.04),梗死区 MPR 无差异。

要点

  • 秋水仙碱显著提高 AMI 后 6 个月远程心肌 MPR,支持微血管获益。
  • 远程区域去神经表面积秋水仙碱组更低,与 MPR 改善一致。
  • 梗死区 MPR 及 MPS 评分(SRS、SSS、SDS)组间无显著差异。

核心结论

  • 秋水仙碱显著增加 AMI 后 6 个月远程心肌 MPR,与交感去神经减少一致,支持秋水仙碱梗死后微血管获益。

研究设计与样本

  • COLD-MI 试验辅助分析,45 例 AMI 后患者随机接受秋水仙碱 30 天或无秋水仙碱。
  • 6 个月时行定量动态 [99mTc]Tc-tetrofosmin SPECT 和 [123I]-mIBG 显像,分析设盲。

主要发现

  • 秋水仙碱组远程心肌 MPR 显著高于对照组(2.37±0.61 vs 1.92±0.53,P=0.01)。
  • 秋水仙碱组远程区域去神经心肌表面积更低(43%[29-50] vs 50%[38-64],P=0.04)。
  • 梗死区 MPR 组间无差异(1.79±0.61 vs 1.60±0.63,P=0.35)。
  • 梗死区去神经有保留更好趋势但未达显著(46%[35-50] vs 50%[45-69],P=0.09)。
  • SRS、SSS、SDS 组间相似。

关键数值与推荐

  • MPR 以 CZT-SPECT 计算为负荷与静息摄取比值。
  • 次要终点包括 MPS 评分(SRS、SSS、SDS)和归一化平均节段活性评估的交感神经支配。

临床怎么用

  • 对 AMI 后患者,秋水仙碱 30 天可能改善远程心肌微血管功能,可用定量动态 SPECT 评估 MPR。
  • MPS 半定量评分可能不足以捕捉秋水仙碱的细微获益,需结合定量 MPR 和 [123I]-mIBG 显像。

局限性

  • 样本量小(45 例),为辅助分析。
  • MPS 可能缺乏敏感性捕捉最小坏死细微变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colchicine reduces sympathetic denervation after acute myocardial infarction (AMI), yet the COLD-MI trial found no change in myocardial perfusion scintigraphy (MPS). MPS-detected necrotic lesions were limited by early management, and MPS may therefore have lacked the sensitivity to capture subtle colchicine-induced variations in minimal necrosis during the immediate post-stenting period. Myocardial perfusion reserve (MPR), a quantitative indicator of global microvascular function, may overcome these limitations. This ancillary analysis of the COLD-MI trial evaluated whether colchicine improves MPR six months after AMI. METHODS: Forty-five post-AMI patients randomized to colchicine for 30 days or no colchicine underwent quantitative dynamic [99mTc]Tc-tetrofosmin SPECT and [123I]-mIBG imaging at 6 months. MPR was quantified using CZT-SPECT as the stress-to-rest uptake ratio. Secondary endpoints included MPS scoring (SRS, SSS, SDS) and sympathetic innervation assessed by normalized mean segmental activity. Analyses were blinded. RESULTS: Colchicine-treated patients showed significantly higher MPR in remote myocardium than controls (2.37 ± 0.61 vs. 1.92 ± 0.53; P = 0.01). Denervated myocardial surface area in remote regions was also lower with colchicine (43% [29-50] vs. 50% [38-64]; P = 0.04). In infarcted myocardium, MPR did not differ (1.79 ± 0.61 vs. 1.60 ± 0.63; P = 0.35). A non-significant trend toward better preserved innervation was observed (denervation: 46% [35-50] vs. 50% [45-69]; P = 0.09). SRS, SSS, and SDS were similar between groups. CONCLUSIONS: Colchicine significantly increases MPR in remote myocardium six months after AMI, consistent with reduced sympathetic denervation and supporting a microvascular benefit of colchicine post-AMI.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Paunet T, Kucharczak F, Dubois J, et al. Association of colchicine use with myocardial perfusion reserve after myocardial infarction: An ancillary analysis of the COLD-MI trial. J Nucl Cardiol. 2026. PMID: 41580017. doi:10.1016/j.nuclcard.2026.102647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。